Serum Institute of India has sought the DCGI's approval for market authorisation of its COVID-19 vaccine- Covovax- as a booster dose for those aged 18 years.
Covaxin and Covishield were granted market approval in India for use in the adult population subject to certain conditions.
An expert panel of India's central drug authority granted regular market approval to Covid vaccines Covishield and Covaxin.
Big boost to India's fight against Covid-19 as Bharat Biotech's vaccine gets approval from Central Drugs Standard Control Organisation (CDSCO).
The UK approved the second 'bivalent' booster for the Omicron variant and original Covid strain.
The clinical trial data showed the booster triggered "a strong immune response" against Omicron variant.
The Centre approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin.
The drive is aimed at boosting the uptake of precautionary doses among all above 18 at a time when the country has been witnessing a surge in cases.
The Union government has invested in developing a strain specific Covid vaccine that would help in countering the changing nature of coronavirus.
The government has reduced the gap between second jab and precautionary dose of coronavirus vaccine to six months.
The Drugs Controller General of India (DCGI) has given a green signal to the country's first indigenous mRNA vaccine against Covid-19, developed by Gennova Biopharmaceuticals.
The first dose of Sputnik V will be given as the booster dose to all those who received Sputnik vaccines. The two doses of Sputnik V vaccine have separate compositions.
The NTAGI on Friday approved Serum Institute of India's Covid-19 vaccine, Covovax, for the 12-17 age group.
Delhi government has announced free booster dose for 18-59 age group. The booster dose is already being provided free of cost to healthcare workers, frontline workers and those above 60 years.
The government panel recommended granting approval to Biological E's Covid-19 vaccine Corbevax for use in children in 5 to 12 years age group.
Britain on Thursday approved the use of Moderna's Covid-19 vaccine in children between six and 11 years.
The UK's medicine regulator on Thursday approved a new vaccine, Valneva, for adult use.
British authorities authorised sixth Covid-19 vaccine for adults made by French drugmaker Valneva. It is the only one that utilizes a "killed" virus.
A third dose of Pfizer and BioNTech's Covid-19 vaccine produced significant protection against the Omicron variant in children between 5 and 11 years of age, as per data from the latest clinical trial.
Minister of Health and Family Welfare Dr Mansukh Mandaviya urged every eligible adult to get their booster dose. He tweeted about the drive being commenced from today.
